Aastrom seeks to raise $12.5 million in stock and warrants exercise:
This article was originally published in Clinica
Aastrom Biosciences (Ann Arbor, Michigan) yesterday announced a common stock placement worth around $9.1m. 8 million shares are being placed with institutional investors at $1.14 per share. The company will also issue warrants that could generate a further $3.4m in revenues. Aastrom and its wholly-owned subsidiary Zellera are optimistic that a second bone-graft trial announced last week will demonstrate the effectiveness of the group's tibial repair technology.
You may also be interested in...
Biogen’s “recipe-driven qualification” knowledge management program standardizes data collection and reporting in the laboratory, with efficiency gains of 66%.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.